SCHEMBL3023162

SCHEMBL3023162

Fc1ccc(-c2nc(Cl)nc3[nH]ccc23)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK1 P23458 1/20 0.46
MAPK14 Q16539 4/20 0.45
IKBKB O14920 2/20 0.44
CHUK O15111 2/20 0.44
CSNK1D P48730 1/20 0.44
MAPK11 Q15759 1/20 0.44
PDK1 Q15118 6/20 0.43
MAPK1 P28482 1/20 0.42
EGFR P00533 2/20 0.41
TXN P10599 1/20 0.41
JAK2 O60674 2/20 0.38
AURKA O14965 1/20 0.38
DAPK3 O43293 1/20 0.38
PRKD3 O94806 1/20 0.38
MAP4K4 O95819 1/20 0.38
PAK4 O96013 1/20 0.38
NTRK1 P04629 1/20 0.38
CSF1R P07333 1/20 0.38
RET P07949 1/20 0.38
IGF1R P08069 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13213033 0.83 JAK2 (0.56) JAK1MAPK14IKBKBCHUKPDK1
SCHEMBL3026919 0.82 AURKA (0.46) JAK1IKBKBCHUKPDK1JAK2
SCHEMBL24528672 0.80 IKBKB (0.45) JAK1IKBKBCHUKPDK1JAK2
SCHEMBL29681139 0.80 IKBKB (0.45) JAK1IKBKBCHUKPDK1JAK2
SCHEMBL3027512 0.77 PDK1 (0.43) JAK1IKBKBCHUKPDK1JAK2
SCHEMBL29479004 0.75 TGFBR1 (0.45) MAPK14CHUKPDK1JAK2DAPK3
SCHEMBL24373220 0.75 TGFBR1 (0.45) MAPK14CHUKPDK1JAK2DAPK3
SCHEMBL27244026 0.73 MAPK1 (0.44) MAPK14CSNK1DMAPK11MAPK1TXN
SCHEMBL30881437 0.73 MAPK1 (0.44) MAPK14CSNK1DMAPK11MAPK1TXN
SCHEMBL20448985 0.73 DYRK1A (0.64) MAPK1JAK2AURKADAPK3PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102307875-A Pyrrolopyrimidinyl axl kinase inhibitors SUPERGEN INC 2012-01-04 CN disclosed
EP-2393814-A1 PYRROLOPYRIMIDINYL AXL KINASE INHIBITORS SuperGen, Inc. (US) 2011-12-14 EP disclosed
US-20100204221-A1 Pyrrolopyrimidinyl axl kinase inhibitors TOLERO PHARMACEUTICALS, INC. 2010-08-12 US disclosed
US-20100204221-A1 Pyrrolopyrimidinyl axl kinase inhibitors TOLERO PHARMACEUTICALS, INC. 2010-08-12 US disclosed
US-20100204221-A1 Pyrrolopyrimidinyl axl kinase inhibitors TOLERO PHARMACEUTICALS, INC. 2010-08-12 US disclosed
WO-2010090764-A1 PYRROLOPYRIMIDINYL AXL KINASE INHIBITORS SUPERGEN, INC. (US) 2010-08-12 WO disclosed
WO-2010090764-A1 PYRROLOPYRIMIDINYL AXL KINASE INHIBITORS SUPERGEN, INC. (US) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204221-A1 Pyrrolopyrimidinyl axl kinase inhibitors AXL, FLT3, TYRO3 JAK1 84/4885MAPK14 169/4885IKBKB 702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.